Merck, Glenmark Rip Zetia Buyers' Par Deal As 'Tactical Move'
Adding Par Pharmaceutical to multidistrict litigation alleging an illegal pay-for-delay agreement to keep a generic version of cholesterol drug Zetia off the market was just a ploy, Merck and Glenmark said...To view the full article, register now.
Already a subscriber? Click here to view full article